Hologic's earnings call for Q3 FY2025 highlighted strong financial performance with revenue and EPS exceeding expectations. The company showed progress in its Breast Health segment and successful integration of acquisitions like Endomagnetics. However, challenges persist in certain markets like China and Africa, which affected diagnostics growth. Overall, the call reflected optimism for future growth despite some ongoing headwinds.

Company Guidance -

Q4 2025

During Hologic's Third Quarter Fiscal 2025 Earnings Call, the company reported financial performance metrics that exceeded guidance. Total revenue for the quarter was $1.024 billion, surpassing the upper end of their guidance by approximately $14 million and showing a slight growth of 0.4% year-over-year. Additionally, Hologic achieved a non-GAAP earnings per share of $1.08, which was a 1.9% increase from the previous year and $0.01 above the high end of their guidance. The company maintained a strong non-GAAP operating margin of just over 30%, despite some tariff impacts. Hologic also noted that their Diagnostics business grew by 0.9% or 2.9% organically when excluding COVID-related sales. The Breast Health segment, although showing a decline of 5.8%, was expected, and the company highlighted improvements in commercial execution and product innovation, particularly in their interventional business, which grew by 31.8%. Looking forward, Hologic is confident in returning to solid mid-single-digit organic revenue growth next year, supported by the strengthening of their Breast Health business and ongoing innovations like the Genius AI Detection PRO software.

Revenue and EPS Exceed Guidance

Hologic delivered revenue of $1.024 billion and non-GAAP EPS of $1.08, both exceeding the company's guidance ranges.

Breast Health Business Improvement

Despite a year-over-year decline, the Breast Health segment showed sequential improvement and surpassed internal expectations, driven by better commercial execution and innovation.

Endomagnetics Acquisition Success

Endomag contributed nearly $20 million in revenue and exceeded deal model expectations, with projections for continued growth.

Interventional Sales Growth

Interventional sales increased 31.8%, with organic growth of 6% excluding acquisitions, driven by the strategic focus of the sales force.

Strong Cash Flow and Financial Flexibility

The company generated $343 million in operating cash flow and maintained a net leverage ratio of 0.6x, indicating strong financial health.

Hologic (HOLX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

HOLX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 03, 2025	2025 (Q4)	1.10 / -	1.01	―	―	―
Jul 30, 2025	2025 (Q3)	1.06 / 1.08	1.06	1.89% (+0.02)
May 01, 2025	2025 (Q2)	1.02 / 1.03	1.03	0.00% (0.00)
Feb 05, 2025	2025 (Q1)	1.01 / 1.03	0.98	5.10% (+0.05)	―
Nov 04, 2024	2024 (Q4)	1.01 / 1.01	0.89	13.48% (+0.12)
Jul 29, 2024	2024 (Q3)	1.02 / 1.06	0.93	13.98% (+0.13)
May 02, 2024	2024 (Q2)	0.98 / 1.03	1.06	-2.83% (-0.03)
Feb 01, 2024	2024 (Q1)	0.95 / 0.98	1.07	-8.41% (-0.09)
Nov 09, 2023	2023 (Q4)	0.84 / 0.89	0.82	8.54% (+0.07)
Jul 31, 2023	2023 (Q3)	0.89 / 0.93	0.95	-2.11% (-0.02)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

HOLX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 30, 2025	$64.98	$66.82	+2.83%
May 01, 2025	$57.28	$54.16	-5.45%
Feb 05, 2025	$72.80	$65.45	-10.10%
Nov 04, 2024	$83.72	$78.80	-5.88%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.